• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • AI Regulatory Developments and Planning Issued by China Regulator

AI Regulatory Developments and Planning Issued by China Regulator

Friday, 18 December 2020 / Published in Medical Device, News, NMPA Registration in China

AI Regulatory Developments and Planning Issued by China Regulator

On November 19, 2020, the Center for Medical Device Evaluation (CMDE) of the National Medical Products Administration (NMPA) published an article to give an overview of the regulatory developments and future plans for AI medical devices. We provide a brief summary as below.

Regulatory development

In 2017, the CMDE established the AI working group to:

  • Learn about the regulatory control and product registration procedure for AI medical devices in other countries
  • Knowledge sharing with related enterprises, research facilities and medical institutions to understand the AI product characteristics, technical specifications, risks for clinical use, etc.
  • Compile a database of AI medical device manufacturers and their related information to follow up on the latest status of industry developments

The CMDE AI working group’s first research project focused on the safety and performance evaluation of three fast growing AI medical devices and the respective real-world data requirements for each product:

  • Diabetic retinopathy auxiliary diagnostic products
  • CT pulmonary nodule auxiliary diagnosis products
  • Pathological image artificial intelligence analysis software

In July 2019, the “Key Points for Deep Learning Aided Decision-Making Medical Device Software Review” was published.

In March 2020, the “Key Points for Evaluation of Pneumonia CT Image Triage and Evaluation Software (Trial)” was published.

In August 2020, two innovative products utilizing AI technology in the field of auxiliary diagnosis of diabetic retinopathy obtained the fast-track approval to enter the China market.

On December 3, 2020, the CMDE announced the plan to implement the “Key Points for the Performance Evaluation of AI Analysis Software for Blood Disease Flow Cytology”. The CMDE is currently asking for feedback from the related manufacturers. The period of consultation lasts until December 31, 2020. Feel free to let us know if you would like to submit a strong proposal together with Cisema.

With more experience gained from the product evaluation process and granting market approvals to more and more AI medical devices in China, the CMDE’s next plan is to implement the technical review guidelines for AI medical devices by 2021.

By Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: AI medical devices

What you can read next

Administrative Measure on Cosmetics Registration and Filing
NMPA Approves Supplementary Testing Methods for Medical Dressing Patches
Important News Concerning CCC Marking

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

two × 4 =

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP